Diabetic Neuropathy

56
rate or flag this page

By Wayne Litchford



Diabetic neuropathy is a nerve disorder of sensory and/or motor nerves that affects up to 50% of patients with Type 2 diabetes. It is frequently seen in older diabetic patients and causes a slowing of nerve conduction.

Diabetic neuropathy can damage nerves in the feet and legs and can cause symptoms such as loss of feeling, numbness, tingling of extremities, and a feeling of wetness of hands, feet, thighs, or other parts of the body.

Sometimes it produces other symptoms that can be painful including sensations of sudden, deep needle-like sticks, feelings of cold or burning, and a deep, dull ache which is exacerbated by the slightest touch or pressure against the affected part. Even clothing rubbing against the affect part can be painful. Any of these symptoms can occur in the same spot and at the same.

Diabetic neuropathy may spread over a large area, or affect several parts of the body, or affect only a specific nerve and part of the body. Skin changes of the arms, hands, legs, and feet can cause hair loss, thin skin, cold clammy sweats, and white, flaky skin (not eczema or psoriasis).

However, one or the most damaging affect of neuropathy is diabetic ulcers. These ulcers are categorized in stages. Stage1 consist of redness of the skin caused by constant pressure on the affected part which decreases blood flow to that area. Stage 2 occurs when the skin becomes broken and can involve damage of the fat tissue and muscle tissue. Stage 3 is when the ulcer exacerbates to the point of muscle damage even to the point of revealing the bone.

Diabetic ulcers occur on the bony prominences of the body such as shoulder, elbow, hips, knees, ankles, and the back of the heel. However, they can be prevented. Relieving the pressure on the bony prominences with pillows and changing position at least every two hours will help promote blood flow and healing. Gently massaging the area is another effective way to increase blood flow.

Another damaging affect of diabetic neuropathy is gangrene. Gangrene most often occurs in the feet and legs. It is a direct result of diabetes’ destruction of vessels and capillaries that feed the cells of the body. Without blood supply, the cells turn a greenish, purple, then finally black when the tissue is dead. The only recourse for gangrene is tissue removal and ultimately amputation of the affected part.

Please Feel Free To Comment

RSS for comments on this Hub

Kulsum Mehmood profile image

Kulsum Mehmood  says:
12 months ago

A very informative write-up on Diabetic Neuropathy Wayne. Thank you for sharing your knowledge.

Wayne Litchford profile image

Wayne Litchford  says:
12 months ago

Thanks so much for reading my hub and leaving such a warm comment. Diabetes affects some many different systems and organs in the body that a person can only write a little bit at a time. Again, I thank you!

Submit a Comment

Members and Guests

Sign in or sign up and post using a hubpages account.


optional


  • No HTML is allowed in comments, but URLs will be hyperlinked
  • Comments are not for promoting your hubs or other sites

Diabetic Neuropathy in the News

  • New GLA source wins FDA approvalNutraingredients.com5 hours ago

    Sonova 400 High GLA Safflower Oil was developed from safflower seeds through a combination of plant breeding and biotechnology, report Arcadia Biosciences Inc and its partner Bioriginal Food and Science Corp which will exclusively market and sell the supplement.

  • Second successful phrenic nerve decompression surgeryNews-Medical-Net14 hours ago

    The Plastic Surgery Center today announced that immediately following a rare phrenic nerve surgery to repair his paralyzed diaphragm, a 47-year-old man has reported significantly improved breathing and feels “15 years younger.” The surgery marked the second known case of successful phrenic nerve decompression, both of which were performed by a New Jersey medical team led by Dr. Matthew Kaufman ...

  • GI Dynamics' EndoBarrier non-surgical type 2 diabetes therapy receives European CE mark approvalNews-Medical-Net32 hours ago

    GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier™, a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking (an acronym for the French "Conformite Europeenne") certifies that a product has met EU requirements for marketing in Europe. Clinical trials ...

  • Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal painNews-Medical-Net2 days ago

    Emisphere Technologies, Inc. today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of calcitonin in filling a significant unmet need for alternative treatments for persistent musculoskeletal pain.

  • New solutions for staying young and healthyLexington Clipper-Herald2 days ago

    (ARA) - As we grow older, we look forward to the changes that life brings - retirement, grandchildren, financial security and travel. Other changes that we might not accept so readily are the aches, pains and mental slowdowns that leave us longing for the good old days of our youth.

  • Raided doctor's patients complain they're 'left out in the cold'The Standard-Times5 days ago

    NEW BEDFORD — "Taylor's orphans" is how they are referred to by some in the local medical community.

  • Health happenings: Dec. 22Bradenton Herald5 days ago

    Send information about free or low-cost health-related events open to the public one week ahead of publication. Information can be e-mailed to jmorreale@bradenton.com. Listings are due 10 days in advance.

  • Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patientsNews-Medical-Net7 days ago

    Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.

Comments

RSS for comments on this Hub

No comments yet.

Submit a Comment

Members and Guests

Sign in or sign up and post using a hubpages account.


optional


  • No HTML is allowed in comments, but URLs will be hyperlinked
  • Comments are not for promoting your hubs or other sites

working